- Home
- GH vs SEM Comparison
GH vs SEM Comparison
Compare GH & SEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GH
- SEM
- Stock Information
- Founded
- GH 2011
- SEM 1996
- Country
- GH United States
- SEM United States
- Employees
- GH N/A
- SEM N/A
- Industry
- GH Medical Specialities
- SEM Hospital/Nursing Management
- Sector
- GH Health Care
- SEM Health Care
- Exchange
- GH Nasdaq
- SEM Nasdaq
- Market Cap
- GH 6.1B
- SEM 2.6B
- IPO Year
- GH 2018
- SEM 2009
- Fundamental
- Price
- GH $47.17
- SEM $20.18
- Analyst Decision
- GH Strong Buy
- SEM Buy
- Analyst Count
- GH 15
- SEM 4
- Target Price
- GH $42.57
- SEM $36.67
- AVG Volume (30 Days)
- GH 2.6M
- SEM 773.7K
- Earning Date
- GH 02-20-2025
- SEM 02-20-2025
- Dividend Yield
- GH N/A
- SEM 2.19%
- EPS Growth
- GH N/A
- SEM 21.44
- EPS
- GH N/A
- SEM 2.14
- Revenue
- GH $692,256,000.00
- SEM $6,968,548,000.00
- Revenue This Year
- GH $32.40
- SEM N/A
- Revenue Next Year
- GH $16.92
- SEM N/A
- P/E Ratio
- GH N/A
- SEM $9.44
- Revenue Growth
- GH 29.20
- SEM 5.80
- 52 Week Low
- GH $15.81
- SEM $13.84
- 52 Week High
- GH $50.89
- SEM $22.08
- Technical
- Relative Strength Index (RSI)
- GH 66.04
- SEM 59.27
- Support Level
- GH $44.10
- SEM $19.29
- Resistance Level
- GH $50.89
- SEM $20.35
- Average True Range (ATR)
- GH 2.75
- SEM 0.54
- MACD
- GH 0.21
- SEM 0.11
- Stochastic Oscillator
- GH 74.24
- SEM 65.97
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About SEM Select Medical Holdings Corporation
Select Medical Holdings Corp is a healthcare company that operates through four main segments: critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and Concentra institutions. Critical illness recovery hospitals and rehabilitation centres are designed for patients requiring extended recovery time with medical services. These two sectors combined compose roughly half of the total revenue and include over 103 critical illness recovery hospitals and inpatient rehab facilities. The outpatient rehabilitation segment includes over 1,928 rehabilitation clinics. The Concentra segment includes over 540 occupational health centers and 147 onsite clinics. The company is headquartered in Pennsylvania, and it operates across the United States.